Navigation Links
MedQuist Files Preliminary Proxy Statement and Applies for Listing on NASDAQ
Date:11/13/2007

MOUNT LAUREL, N.J., Nov. 13 /PRNewswire-FirstCall/ -- MedQuist Inc. (Pink Sheets: MEDQ.PK) announced today that it filed a preliminary proxy statement for the solicitation of proxies for an annual meeting of shareholders with the Securities and Exchange Commission (SEC). The Company is, as announced on November 9, 2007, proceeding with its search for three independent directors to add to the Board currently and then to nominate for election at an annual meeting of shareholders which the Company plans to hold within 30 days of the date on which its definitive proxy statement is mailed to shareholders.

In addition to filing the preliminary proxy statement, the Company today also submitted its application for listing on the NASDAQ Global Select Market. The Company's common stock has traded on the over-the-counter "Pink Sheets" market under the symbol "MEDQ.PK" since June 16, 2004, the date on which its common stock was delisted from the NASDAQ National Market.

NOTICE TO SHAREHOLDERS:

In connection with the Company's upcoming annual meeting of shareholders, the Company will be filing a proxy statement and potentially other relevant documents concerning the annual meeting with the SEC. BEFORE MAKING ANY DECISION REGARDING ANY OF THE BUSINESS PROPERLY BROUGHT BEFORE THE ANNUAL MEETING, SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders can obtain free copies of the proxy statement and other relevant documents concerning the annual meeting that have been filed with the SEC when they become available by contacting Investor Relations, MedQuist Inc., 1000 Bishops Gate Blvd., Suite 300, Mt. Laurel, NJ 08054. In addition, documents filed with the SEC will be available at no charge on the SEC's website at http://www.sec.gov. The Company and its executive officers and directors may, under SEC rules, be deemed to be participants in the solicitation of proxies from shareholders of the Company in connection with the upcoming annual meeting. Certain information about such individuals (including their ownership of shares of the Company's common stock) is set forth in the Company's Form 10-K for the year ended December 31, 2006, which is available free of charge from the SEC and the Company as indicated above.

About MedQuist:

MedQuist is a leading provider of clinical documentation workflow solutions in support of the electronic health record. MedQuist provides electronic medical transcription, health information and document management products and services, including digital dictation, speech recognition, Web- based transcription, electronic signature, medical coding, mobile dictation devices, and outsourcing services.

Disclosure Regarding Forward-Looking Statements:

Some of the statements in this Press Release constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are not historical facts but rather are based on the Company's current expectations, estimates and projections regarding the Company's business, operations and other factors relating thereto. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expects," "intends," "plans," "projects," "believes," "estimates" and similar expressions are used to identify these forward-looking statements. The forward-looking statements contained in this Press Release include, without limitation, statements about the timing of and business to be brought before an upcoming annual meeting of the shareholders of MedQuist. These statements are only predictions and as such are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, including, without limitation, the risk that MedQuist is unable to identify independent directors to add to the Board. For a discussion of these risks, uncertainties and assumptions, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of MedQuist Annual Report on Form 10-K for the year ended December 31, 2006, entitled "Risk Factors" and discussions of potential risks and uncertainties in MedQuist's subsequent filings with the SEC.


'/>"/>
SOURCE MedQuist Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. MedQuist Re-launches New, Improved Web Site
2. MedQuist Updates Status of Outstanding SEC Filings
3. MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions
4. MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders
5. Alvarado Hospital Files Countersuit Against Blue Shield
6. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Gentiva(R) Health Services Files Universal Shelf Registration Statement
9. Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
10. CIGNA Behavioral Health Offers Members Online Provider Profiles
11. American Media Operations, Inc. Files Form 10-Q For First Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , ... December 04, 2016 , ... ... major cosmetic surgery can now take advantage of a cosmetic procedure known as ... rejuvenation treatment that reduces the appearance of age spots, fine lines, uneven ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges ... brush properly to achieve optimal results. This important necessity inspired an inventor from Las ... a way to ensure that people break or avoid bad techniques of brushing the ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host ... honoring the 2016 MPN Heroes—eight individuals who have made a difference in the field ... the standard of care, demonstrating leadership within the MPN community and/or a commitment to ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 ... hydroxyurea (HU) in Complete Hematologic Response (CHR) ... ropeginterferon alfa-2b versus HU AOP will submit ... CONTINUATION-PV to obtain European marketing authorization in the coming months ... the FDA as it seeks approval for commercialization in the ...
(Date:12/4/2016)... 2016 Sickle cell disease (SCD) is an ... cells that get stuck in veins and block blood ... and complications leading to death. Each year, approximately 300,000 ... most of them lack access to comprehensive care or ... therapy for SCD, a pill called hydroxyurea approved more ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology: